CLUSTER TRAINING + CREATINE PROJECT
NCT07924150, Not applicable, Completed, Dynamical Business and Science Society - DBSS International SAS
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | CLUSTER TRAINING + CREATINE PROJECT | ClinicalTrials.gov |
| NCT number | NCT07924150 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 28 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Dynamical Business and Science Society - DBSS International SAS | ClinicalTrials.gov |
| Conditions | Sarcopenia in Elderly, Creatine Supplementation, Resistance Exercise | ClinicalTrials.gov |
| Interventions | Cluster Training plus Creatine Supplementation, Cluster Training plus placebo | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Stature in meters | From enrollment to the end of treatment at 8 weeks | Stature was measured using a stadiometer (SECA, model 213; Seca Corp., Hanover, MD, USA) with a measurement range of 20-205 cm and 1 mm increments. Participants were positioned standing, barefoot, with their heads oriented in the Frankfort plane | ClinicalTrials.gov |
| Primary | Body mass in kilograms | From enrollment to the end of treatment at 8 weeks | Body mass was measured using an Omron bioelectrical impedance body composition monitor (model HBF-514C; Omron Healthcare, Inc., USA), which has a measurement range of 2-150 kg with 0.1 kg increments. Participants were instructed to stand upright and steady on the scale, looking straight ahead, with their arms extended at their sides. | ClinicalTrials.gov |
| Primary | Body composition | From enrollment to the end of treatment at 8 weeks | Whole and regional body composition were estimated using dual-energy X-ray absorptiometry (DXA). Each subject was scanned by a certified technician, and the dis-tinguished bone and soft tissue, edge detection, and regional demarcations were per-formed by computer algorithms (software version enCORE™ 16.0, Lunar Prodigy Ad-vanced, GE Medical System Lunar, Madison, WI). The variables that will be taken into account are lean soft tissue in kilograms, fat-free mass in kilograms, body fat percentage, fat mass in kilograms, visceral adipose tissue in grams, bone mineral content in grams, and bone mineral density in grams per square centimeter. | ClinicalTrials.gov |
| Primary | Timed Up & Go test in seconds to assess the risk of falling | From enrollment to the end of treatment at 8 weeks | It is used to assess fall risk and functional mobility in older adults. A chair without armrests, with a firm backrest and a seat height of approximately 46 centimeters, is used. A mark is placed three meters in front of the chair. The individual is asked to sit with their back against the backrest and their feet planted firmly on the floor. Upon the evaluator's signal, the patient must stand up from the chair as quickly and safely as possible, walk to the three-meter mark, turn around it, and return to the chair, sitting back down with their back against the backrest. Timing begins at the evaluator's signal and ends the moment the patient sits down. | ClinicalTrials.gov |
| Primary | gait test in seconds | From enrollment to the end of treatment at 8 weeks | Assess walking speed. A four-meter path is marked out on a flat surface, free of obstacles. The patient is instructed to begin walking as quickly as possible upon a given signal. The time taken from the start to the four-meter mark is measured. | ClinicalTrials.gov |
| Primary | Chair-stand test in seconds | From enrollment to the end of treatment at 8 weeks | Assess lower-limb strength. Use a sturdy chair without armrests. Ask the patient to sit with their arms crossed over their chest, then stand up and sit back down. Record the time taken to complete five full repetitions. | ClinicalTrials.gov |
| Primary | Estimated maximum force in pounds | From enrollment to the end of treatment at 8 weeks | The Brzycki equation (Brzycki, 1993) will be used to estimate one-repetition maximum (1RM) strength for the following exercises: leg press, leg curl, leg extension, squat, bench press, and row. This formula is validated for predicting maximum strength in older adults, given its high correlation with direct 1RM measurement. The procedure will begin with a familiarization phase involving the equipment and exercises to be performed. Following a general warm-up, a specific warm-up will be conducted for each piece of equipment (8 to 10 repetitions at 40% of the perceived maximum weight). To estimate the 1RM, a weight representing approximately 75% of the perceived maximum will be selected; participants will perform repetitions at a controlled speed, with encouragement to complete as many repetitions as possible until reaching failure. The weight lifted and the number of correctly completed repetitions will be recorded and then entered into the formula developed by Brzycki: 1RM = weight lif | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)